Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $264,144.14 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 9,074 shares of Akero Therapeutics stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $29.11, for a total value of $264,144.14. Following the completion of the sale, the insider now owns 95,648 shares of the company’s stock, valued at approximately $2,784,313.28. The trade was a 8.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Friday, November 15th, Catriona Yale sold 9,061 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.73, for a total transaction of $251,261.53.
• On Friday, November 1st, Catriona Yale sold 15,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.62, for a total transaction of $505,120.70.
• On Wednesday, October 30th, Catriona Yale sold 4,515 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.53, for a total transaction of $146,872.95.
• On Monday, October 14th, Catriona Yale sold 6,136 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.03, for a total transaction of $184,264.08.
• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.65, for a total value of $152,075.00.

Akero Therapeutics Stock Performance

Shares of Akero Therapeutics stock opened at $29.34 on Friday. The company has a market cap of $2.05 billion, a PE ratio of -7.82 and a beta of -0.23. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 52 week low of $15.32 and a 52 week high of $37.00. The business has a 50 day moving average price of $30.89 and a 200-day moving average price of $27.44.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). Equities analysts anticipate that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AKRO. Mirae Asset Global Investments Co. Ltd. increased its stake in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after buying an additional 446 shares during the last quarter. Y Intercept Hong Kong Ltd increased its position in shares of Akero Therapeutics by 13.8% during the third quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company’s stock valued at $485,000 after acquiring an additional 2,049 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in Akero Therapeutics by 12.4% during the third quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company’s stock worth $574,000 after acquiring an additional 2,200 shares during the period. LMR Partners LLP boosted its position in Akero Therapeutics by 17.0% in the third quarter. LMR Partners LLP now owns 20,597 shares of the company’s stock worth $591,000 after purchasing an additional 2,997 shares during the last quarter. Finally, Eastern Bank bought a new position in Akero Therapeutics in the 3rd quarter valued at $100,000.

Analyst Ratings Changes

Several research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a report on Monday, November 18th. Citigroup began coverage on Akero Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $65.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $46.83.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.